| Overview |
| bs-13221R |
| FSD1L/CCDC10 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Rat |
| Mouse, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FSD1L/CCDC10 |
| 221-320/530 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 83856 |
| Nucleus |
| CCDC10; Coiled-coil domain-containing protein 10; CSDUFD1; FSD1 N-terminal-like protein; FSD1-like protein; FSD1CL; Fsd1l; FSD1L_HUMAN; FSD1NL. |
| FSD1L is a 530 amino acid protein containing one B30.2/SPRY domain, one COS domain, and a fibronectin type-III domain. Existing as three alternatively spliced isoforms, FSD1L is expressed primarily in brain, with lower levels of expression found in thymus, pituitary and testis. FSD1L may function in microtubule binding during interphase and is encoded by a gene that maps to human chromosome 9q31.2. Chromosome 9 consists of about 145 million bases andd comprises approximately 4% of the human genome and encodes nearly 900 genes. Considered to play a role in gender determination, deletion of the distal portion of 9p can lead to development of male to female sex reversal, the phenotype of a female with a male X,Y genotype. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz